A hormone secreted by fat cells can restrain the growth of liver tumors in mice, according to a new study.
The findings offer a proof-of-concept for developing therapies against hepatocellular carcinoma, the most common form of liver cancer.
Jiandie Lin and his team use mice as a model to study how molecular and cellular changes are affected by nonalcoholic fatty liver disease, and how these changes consequently lead to the progression of this disease. While it begins as a relatively benign accumulation of fat in the liver, the disorder can develop into nonalcoholic steatohepatitis, or NASH, which increases the risk for liver cancer.
The liver contains scores of different cell types, including various immune cells. Using single-cell RNA sequencing, a technology for probing gene expression of individual cells within complex tissues, Lin and his team previously constructed a liver cell atlas and a blueprint of intercellular signaling in healthy and NASH mouse livers.
For this latest study, published in the journal Cell Metabolism, the scientists wanted to identify specific molecular changes in the NASH state that disrupt balance and interactions of these cell types, as potential therapeutic targets to reverse the progression from NASH to cancer.
“Liver cancer in NASH patients is different from cancers caused by viral hepatitis, in that it often develops in the absence of liver cirrhosis,” says Lin, a faculty member at the University of Michigan Life Sciences Institute and the study’s senior author. “We suspect that different disease mechanisms may be engaged in NASH-related liver cancer.”
Lin and colleagues observed changes in two types of immune cells in particular that appear to contribute to the development of HCC. In mouse livers with NASH, T cells—the immune cells that normally fight infected or damaged cells, such as cancerous cells—showed hallmarks of functional impairments. At the same time, the team found that a second type of immune cell, called macrophages, acquired molecular features typically associated with cancers.
“These changes we saw in macrophages and T cells resemble the tumor microenvironment, but they are happening even before any cancer becomes apparent,” says Lin, who is also a professor of cell and developmental biology at the University of Michigan Medical School. “It gives us a hint that maybe these changes in the liver microenvironment could provide fertile ground for liver cancer cells to appear and grow. It almost looks like the liver, once it develops NASH, is already preparing for cancer cells to thrive.”
The team also identified a hormone that serves as a checkpoint for disease progression, and it appears to have potential as a treatment: neuregulin 4, or NRG4.
Lin’s team previously revealed that NRG4—a hormone that is secreted primarily by fat cells—can protect mouse livers against NASH, and that a decrease or loss of this hormone leads to more severe levels of liver disease.
Now, the team has found that the hormone can suppress hepatocellular carcinoma in NASH mice. Their findings show that mice lacking the hormone NRG4 develop more severe NASH and more liver tumors than mice with normal levels of NRG4.
When the scientists boosted levels of the hormone in mice—either by genetically elevating the expression of NRG4 in fat tissues or by treating mice with a recombinant NRG4 fusion—the increased levels of NRG4 suppressed NASH liver cancer progression.
“A lot of studies on liver cancer focus on the cancerous liver cells themselves: how they proliferate and how they evade the immune system,” Lin says. “But our findings break out of this liver-centered framework, showing a fat-derived hormone could actually reprogram the liver environment and have a very big impact on liver cancer development.”
More research is needed before NRG4 can be pursued as a therapeutic for hepatocellular carcinoma. Lin and his team now plan to investigate approaches for improving the hormone’s effectiveness and to better understand the nature underlying its regulation of macrophages and T cells in the liver.
The research had support from the National Institutes of Health and the University of Michigan Rogel Cancer Center.
Source: University of Michigan